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Complexes comprised of IGF-I, IGF-binding proteins and the ECM protein vitronectin (VN) 
stimulate cell migration and growth and can replace the requirement for serum for the ex vivo 
expansion of cells, as well as promote wound healing in vivo. Moreover, the activity of the 
complexes is dependent on co-activation of the IGF-I receptor and VN-binding integrins. In 
view of this we sought to develop chimeric proteins able to recapitulate the action of the 
multiprotein complex within a single molecular species. We report here the production of two 
recombinant chimeric proteins, incorporating domains of VN linked to IGF-I, which mimic 
the functions of the complex. Further, the activity of the chimeric proteins is dependent on co-
activation of the IGF-I- and VN-binding cell surface receptors. Clearly the use of chimeras 
that mimic the activity of growth factor:ECM complexes, such as these, offer manufacturing 
advantages that ultimately will facilitate translation to cost-effective therapies. 
 
3 
Introduction 
 
The insulin-like growth factors (IGFs) have well-established roles as potent mitogens and cell 
survival factors. As such, the IGFs have been actively investigated as therapeutics and as 
critical ingredients in many cell culture media (Morris et al. 1994; Sunstrom et al. 2000). We 
recently discovered novel links between IGFs and the ECM protein vitronectin (VN) and have 
reported that IGF-II can bind directly to VN (Upton et al. 1999), while IGF-I binds indirectly 
via IGF-binding proteins (IGFBP)-2, -3, -4 and -5 (Kricker et al. 2003), resulting in dimeric 
and trimeric complexes, respectively. These interactions are potentially very significant as 
VN is a protein that is abundant not only in tissues, but also in the circulation (0.4 mg/ml) 
(Schvartz et al. 1999); hence it is also a major constituent of serum that is commonly required 
to maintain the survival and expansion of mammalian cells in vitro and ex vivo. Indeed, our 
studies investigating the outcomes of the interaction of IGFs with VN have revealed that these 
complexes significantly enhance migration and proliferation in a variety of cells (in the 
absence of serum) including human breast epithelial (Noble et al. 2003), osteoblast-like 
(Schleicher et al. 2005), and skin and corneal epithelial cell lines (Hyde et al. 2004; Hollier et 
al. 2005). Importantly, studies using keratinocytes derived from adult human skin and the 
limbal region of adult cornea, as well as osteoblast-progenitor cells derived from alveolar 
bone chips, have validated these findings (Hyde et al. 2004; Hollier et al. 2005; Schleicher et 
al. 2005; Ainscough et al. 2006; Dawson et al. 2006). Moreover, we have demonstrated that 
these complexes can substitute for serum, enabling the serum-free ex vivo serial expansion of 
cells used in cell-based therapies (Ainscough et al. 2006; Dawson et al. 2006) and can also 
promote wound healing in vivo (Upton et al. 2007). These data led us to hypothesise that VN 
may have a role in facilitating more effective “delivery”, or “presentation” of growth factors 
to cells. This represents a paradigm shift; however, it more closely mimics the situation that 
cells encounter in the body. Indeed, the importance of interactions between growth factors 
and proteins other than "classic signalling" receptors in the extracellular milieu is now 
generally considered to be a process critical to a range of cellular functions (Giancotti and 
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Ruoslahti 1999). Furthermore, recent investigations within our research program have 
demonstrated that functional responses to these novel complexes are dependent on the 
co-activation of the IGF-1R and the αv-integrins (Hollier et al. 2005; Hollier et al. 2007; 
Upton et al. 2007). 
In view of the significant functional responses induced by these novel complexes in 
vivo and in vitro we believe the VN:IGFBP:IGF-I complex technology has the potential to be 
translated into defined culture reagents and effective clinical treatments. The translation 
process would, however, be significantly constrained by the complex methodology and cost 
required to generate and incorporate 3 recombinant proteins into one bioactive therapy. Thus 
we investigated whether the VN:IGFBP:IGF-I complex-induced cellular responses, 
particularly cell growth and migration, could be reproduced using chimeric proteins that 
incorporate the essential features of both the VN and IGF proteins. Such a mimetic protein 
would in turn facilitate the translation of the VN:IGF-I approach into approved clinical and 
industrial products more cost-effectively compared to the multi-protein complex. We report 
here the generation of recombinant proteins, including full-length and truncated forms of VN 
linked to IGF-I, to form four novel chimeric proteins. Further, we have confirmed that two of 
these chimeric proteins elicit similar cellular responses to that found with the multimeric 
VN:IGFBP:IGF-I complexes and provide evidence that co-activation of both the VN-binding 
αv-integrins and the IGF-1R is critical to these responses. 
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Materials and methods 
 
Reagents and materials. Human IGF-I was purchased from GroPep (Adelaide, SA, Australia), 
human VN was purchased from Promega (Annandale, NSW, Australia), while IGFBP-3 was 
purchased from Upstate Biotech (Lake Placid, NY, USA). For receptor blocking studies, 
monoclonal antibodies directed against the integrin αv-subunit (AV1) and the mouse IgG iso-
type matched control antibody were purchased from Chemicon (Temecula, CA, USA), while 
the monoclonal antibody against the IGF-1R (αIR3) was purchased from Merck Biosciences 
(Kilsyth, VIC, Australia). For immunoblotting studies, rabbit polyclonal anti-VN antibody 
was purchased from Calbiochem (San Diego, CA, USA), while anti-ERK 1/2 rabbit 
polyclonal, anti-phospho ERK1/2 MAPK (Thr 202/ Tyr 204) (E10), anti-AKT mouse 
monoclonal (2H10) and anti-phospho-AKT (Ser 473) (193H12) antibodies were purchased 
from Cell Signaling Technology (Beverly, MA, USA). All other reagents were purchased 
from Sigma-Aldrich (Castle Hill, NSW, Australia) unless otherwise stated. All manipulations 
using VN or IGFBP were performed using low protein adhesion or siliconised plastic-ware 
and tips. 
 
Cell culture. The MCF-7 human breast carcinoma cell line (HTB-22, ATCC, Manassas, VA) 
used in this study was cultured in DMEM/Ham’s F-12 (DMEM/F12) media (1:1) (Invitrogen, 
Mulgrave, VIC, Australia) containing 10% fetal bovine serum (FBS) (HyClone, South Logan, 
UT, USA), 0.1 µg/mL streptomycin, 50 units/mL penicillin and 1 µg/mL gentamycin. All 
cultures were passaged every 2-3 days by trypsin/EDTA detachment. For use in bioassays, 
cells were serum-starved by incubation in serum-free and phenol-red free DMEM/F12 (1:1) 
(SFM) for 4 hours prior to trypsinization and seeding into tissue culture vessels. Spodoptera 
frugiperda (Sf9) insect cells were purchased from Invitrogen and were cultured in SF-900 II 
serum-free media (Invitrogen). Transfected cultures were maintained in shaker flasks of up to 
0.5 L culture volume and were passaged to a viable density of 2 x 106 cells/mL every 2-3 
days. 
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Engineering, expression and purification of the chimeric proteins. Human VN and IGF-I gene 
DNA sequences (NCBI accession # AF382388 and #X03563, respectively) were codon-
optimised for expression in Spodoptera frugiperda and synthesised by GeneArt (Regensburg, 
Germany). The coding sequences were then cloned into the pIB/V5-His expression vector 
(Invitrogen) incorporating a poly-histidine affinity tag to aid in the purification of the 
chimeras. A nucleotide sequence encoding a (Gly4Ser)4Asn amino acid linker was inserted via 
site-directed mutagenesis polymerase chain reaction (PCR). The addition of an Asn to the C-
terminus of the linker sequence was used to generate a Asn-Gly motif with Gly being the first 
amino acid of IGF-I. This motif enables hydroxylamine induced cleavage of the IGF-I protein 
from the chimeras. The resulting construct, referred to as Chimera A, encodes the full-length 
mature VN protein (amino acids 1-459) linked by (Gly4Ser)4Asn to the full-length mature 
IGF-I protein (amino acids 1-70). Three chimeras containing truncated portions of VN, 
chimeras B (VN amino acids 1-311), C (VN amino acids 1-125) and D (VN amino acids 1-
64), were also produced by deletion of selected regions of the VN gene via additional rounds 
of site directed mutagenesis PCR (see Table I for primer sequences). The DNA sequence of 
all constructs were verified to ensure that the fidelity of the desired DNA sequences were 
maintained. Clones in the pIB/V5-His vector were used to transfect Sf9 insect cells and 
transiently-expressed secreted protein was detected in the conditioned media, as assessed by 
immunoblotting. Briefly, the samples were resolved on SDS-PAGE under reducing 
conditions (Laemmli 1970) and the proteins were transferred onto a nitrocellulose membrane 
using a semi-dry transfer method (Bjerrum and Schafer-Nielsen 1986). The membrane was 
interrogated with poly-clonal anti-VN antibodies and the target protein species were then 
visualized using enhanced chemiluminescence following the manufacturer’s instructions (GE 
Healthcare, Buckinghamshire, UK). 
[Insert Table I about here] 
 Purification of the chimeric proteins was based on Ni-NTA Superflow Agarose 
(QIAGEN, Australia) affinity chromatography performed according to the manufacturer’s 
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instructions.  The chimeric proteins were monitored throughout the purification process by 
SDS-PAGE and western blot analysis using a poly-clonal anti-VN antibody (Calbiochem).  
For Chimera A, clarified culture media was loaded onto a 2 mL Ni-NTA Superflow Agarose 
column equilibrated with 100 mM NaH2PO4, 10 mM Tris.Cl, pH 8.0 and material was eluted 
in the same buffer containing 8 M Urea at pH 4.5. The eluate was neutralised by dilution with 
20 mM Na2HPO4, 8 M Urea, pH 7.4 before batch mode adsorption onto 10 mL of Heparin-
sepharose resin equilibrated with the same buffer.  Following binding, the resin was packed 
into a column and washed with 20 mM Na2HPO4, 8 M Urea, 150 mM NaCl, pH 7.4 and 
bound protein was eluted across a 0.15-1.5 M NaCl gradient at a flow rate of 1 mL/min.  
Fractions containing VN-immunoreactive protein were pooled and diluted in 100 mM 
NaH2PO4, 10 mM Tris.Cl, pH 8.0 before loading onto a second Ni-NTA Superflow Agarose 
column. After processing as above, fractions containing Chimera A were pooled and dialysed 
against 100 mM NaH2PO4, pH 7.4 containing 1.5 M NaCl.  Total protein was precipitated by 
the addition of 40% (w/v) ammonium sulphate and the centrifuged protein pellet was 
resuspended in Dulbecco's Phosphate Buffered Saline (Invitrogen).  
 Chimeras B and C were purified using a similar method, however, Q-sepharose resin 
(GE Healthcare) was used in place of Heparin-sepharose. Purification of Chimera D was 
achieved through the exclusive use of 2 passes on Ni-NTA Superflow Agarose as describe 
above. The chimeric preparations were quantified via UV spectrophotometry using calculated 
extinction co-efficients at A280nm (Wilkins et al. 1999).  Purity of the preparations was 
assessed by silver stained SDS PAGE and was shown to be >90% (data not shown).  
 
Transwell™ migration assays. As the MCF-7 cell line migrates poorly in the absence of 
serum and attachment factors, it is an ideal cell line to examine the effects of candidate factors 
as stimulators of migration (Noble et al. 2003). Migration assays were performed as 
previously described by our laboratory (Noble et al. 2003; Hyde et al. 2004; Hollier et al. 
2005). Briefly, experimental treatments were added to the lower chamber of the TranswellTM 
plate immediately prior to cell harvesting and seeding into Tranwells™ (see Table II for 
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treatment schedule). Cells which has been serum-starved for 4 hours prior to trypsinisation 
were seeded at a density of 2 x 105 cells/well in SFM + 0.05% BSA into the upper chamber of 
Transwell inserts (12 µm), while the treatments were dispensed into the lower Transwell 
chambers. In some experiments the cells were pre-incubated with the indicated concentrations 
of inhibitory antibodies for 30 minutes at room temperature prior to seeding into the 
Transwell. Plates containing the Transwell inserts were then incubated for 5 hours at 
37°C, 5% CO2. Cells which had migrated to the lower surface of the membrane were fixed in 
10% para-formaldehyde and stained with 0.023% Crystal Violet in phosphate buffered saline. 
The number of cells which had migrated to the lower surface of the porous membrane was 
then quantified by extracting the crystal violet stain in 10% acetic acid and determining the 
optical density of these extracts at 595 nm (Leavesley et al. 1993).  
[Insert Table II about here] 
 
N-terminal sequencing and Mass-spectroscopy. Pure preparations of chimera B and 
chimera D were reduced and alkylated with 10 mM dithiothreitol (DTT) and 50 mM 
iodoacetamide (IAA). Samples were then electrophoresed on a 15% separating SDS-PAGE 
and transferred onto a sequence grade PVDF membrane (Bjerrum and Schafer-Nielsen 1986). 
The transferred proteins were stained with Ponceau S and the bands corresponding to the pure 
chimeras were excised and transferred to microcentrifuge tubes. The samples were then 
processed to determine the N-terminal 8 amino acids by the Australian Proteome Analysis 
Facility (APAF) (Sydney, NSW, Australia) using the Edman degredation method (Edman 
1950). Peptide Mass Fingerprinting was also performed to confirm amino acid sequence 
fidelity. In brief, the chimeric proteins were run on a 4-12% gradient SDS-PAGE gel, the 
bands were excised and the proteins were reduced with 10 mM DTT and alkylated with 55 
mM IAA. Sequence grade trypsin (Promega) was then added and the proteins were digested 
for 16 hr at 37oC. The eluted peptides were spotted onto a target plate in a 1:1 mixture with 5 
mg/mL α-cyano-4-hydroxycinnamic acid in 5 mM ammonium phosphate:60% acetonitrile 
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and allowed to air dry. The plate was then analysed using a Voyager DE-STR MALDI-TOF 
(Applied Biosystems, Foster City, CA, USA) mass spectrometer and the data were processed 
using the FindPep program available from the expasy website (www.expasy.org). 
 
Assessment of signal transduction pathways. For ERK 1/2 and AKT activation, the 
experimental treatments were added to the wells of a 6-well plate immediately prior to cell 
harvesting (see Table III for treatment schedule). Serum-starved cells were then harvested 
and resuspended in SFM + 0.05% BSA and allowed to recover for 30 minutes at 37°C, 5% 
CO2. Cells were then seeded into the wells of 6-well plates containing protein treatments and 
incubated at 37°C, 5% CO2 for the times indicated. Cells were lysed in Radio 
Immunoprecipitation Buffer (RIPA) containing 2 mM Na3VO4, 10 mM NaF and were 
subsequently interrogated via immunoblotting using antibodies specific for the activated 
forms of the signaling molecules. Protein species were then visualized using enhanced 
chemiluminescence following the manufacturer’s instructions (GE Healthcare). The same 
membranes were subsequently stripped and total levels of ERK 1/2 and AKT were detected to 
validate equal loading. 
[Insert Table III about here] 
 
Cell proliferation assays. The ability of select chimeric proteins to promote MCF-7 cell 
proliferation was assessed in cell growth assays utilising a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS)-based assay 
system (Cory et al. 1991). The treatments were diluted in SFM to concentrations equivalent to 
those used in the migration assays in a total volume of 50 µL (see Table IV for treatment 
schedule). Subsequently 5,000 cells in SFM (50 µL) were added to each well and incubated at 
37oC, 5% CO2 for 96 hours. MTS reagent was then added and the cells were incubated for a 
further 2 hours at 37oC, 5% CO2 in order to allow the tetrazolium salt colour to develop. 
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Absorbance was read at 490 nm in a Beckman Coulter microplate reader (Beckman Coulter, 
Fullerton, CA, USA) and the results were expressed as percentage above SFM. 
[Insert Table IV about here] 
 
Statistical Analysis. The data is expressed as a percentage of the response observed in either 
wells containing SFM or VN alone, unless otherwise stated in the Figure Legends. The data 
was pooled from replicate experiments with each treatment tested separately in each 
experiment in at least duplicate wells (refer to Figure Legends). Data analysis was performed 
using ANOVA with Dunnets and Tukeys post hoc tests performed where appropriate. 
Statistical confidence was determined at 95% level  (p<0.05). 
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Results 
 
Production of four VN:IGF-I chimeric proteins. As detailed above, we sought to develop 
chimeric proteins able to recapitulate the action of the VN:IGFBP:IGF-I multiprotein 
complex within a single molecular species. We have designed, expressed and purified 4 
recombinant chimeric proteins incorporating specific domains of VN linked to mature IGF-I 
(a schematic representation and amino acid sequences are depicted in Fig. 1). A series of 
chimeric expression constructs were designed in which various lengths of the VN protein 
were linked to the full-length mature IGF-I protein. Modification of the IGF-I protein was not 
pursued due to the discontiguous nature of the multiple sites in IGF-I that have been reported 
to interact with the IGF-1R (Cascieri et al. 1988; Bayne et al. 1989; Bayne et al. 1990; Denley 
et al. 2005; Keyhanfar et al. 2007). The first chimeric protein, chimera A, was designed to 
contain the complete mature VN sequence (amino acids 1-459) linked to IGF-I. Chimera B 
contains VN amino acids 1-311, creating a C-terminally-truncated VN without the 
heparin-binding domain, while chimera C, encoding amino acids 1-125 of VN, contains the 
somatomedin-B (SMB) domain as well as the connecting region of VN. This region is 
suggested to play a role in binding the thrombin-antithrombin complex as well as collagen 
(Schvartz et al. 1999). The shortest construct design, chimera D, contains amino acids 1-64 of 
VN and therefore includes the SMB domain, RGD integrin binding site and the acidic region 
as its basic functional elements. The acidic region was retained as it is thought to be pertinent 
to the function of VN whilst also allowing the binding of additional growth factors (Schvartz 
et al. 1999). In each case, the VN segments were linked to the mature IGF-I sequence via a 
(Gly4Ser)4Asn linker.  
[Insert Figure 1 about here] 
 The four VN:IGF-I chimeric molecules were successfully expressed in Sf9 insect 
cells and were then purified from the conditioned media using heparin-sepharose, Q-
sepharose and Ni2+-NTA agarose under native and denaturing conditions as described in the 
Materials and Methods section. Western-blot analysis revealed that all four recombinant 
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proteins cross-react with a poly-clonal anti-VN antibody, while silver-stained SDS-PAGE 
analysis demonstrated purities >90% (Fig. 2).  
[Insert Figure 2 about here] 
 
Cell migration. The four chimeric molecules were assessed compared side-by-side with the 
VN:IGFBP-3:IGF-I complex in MCF-7 cell migration assays (Fig. 3). The treatments were 
added in molar ratio according to the VN portion of the protein; hence 1x VN equals 1 µg of 
VN per mL. The data are expressed as % of the 1x VN alone treatment (1 µg/mL) (100%) and 
indicates that the VN:IGFBP-3:IGF-I complex treatment stimulated migration to 
approximately 280%. Chimera A was unable to stimulate cell migration as effectively as the 
VN:IGFBP-3:IGF-I complex, enhancing migration only 37% above the 1x VN only control at 
its highest dose (10x). Although chimera B was no more active than chimera A at low 
concentrations (1x and 3x), the migration response observed with chimera B at 10x (300%) 
was equivalent to that found with VN:IGFBP-3:IGF-I complexes. The third chimera, C, did 
not significantly increase cell migration above the negative control (67% and 31% 
respectively). With respect to chimera D, the 1x, 3x and 10x treatments were not dissimilar to 
the VN alone treatments. However, 30x chimera D was able to promote cell migration to 
similar levels as found with the 1x VN:IGFBP-3:IGF-I complex, that is 240%. Further, both 
chimeras B and D stimulated MCF-7 cell migration in a dose-responsive manner. 
[Insert Figure 3 about here] 
 
N-terminal sequencing and Mass-Spectrum analysis of chimeric proteins. The chimeras of 
interest after assessment in the migration assay described above, namely chimeras B and D, 
were interrogated to determine whether the N-terminal signal peptide had been correctly 
cleaved. Hence, samples of chimeras B and D were processed as described in the Materials 
and Methods section and their N-terminal 8 amino acids deduced via Edman degradation. 
Both chimeras B and D returned a sequence complementary to that expected for native VN 
with the secretion peptide (amino acids 1 – 19) removed (see Table V). A blank at position 5 
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indicates a Cysteine residue or another modified amino acid. In the expected sequence for 
mature VN a Cysteine (C) is positioned at residue 5, therefore the sequence results confirm 
that the constructs have been successfully produced as designed. N-terminal sequencing was 
only performed on chimeras B and D but the same result can be extrapolated to chimeras A 
and C as there are no amino acid differences between all 4 chimeras at the N-terminus, nor 
were the expression conditions different.  
[Insert Table V about here] 
 However, to provide a broader picture of post-translational protein modifications, all 
4 chimeras were also assessed in Mass-Spectroscopy experiments along with human VN 
(Promega) as a control (Table VI). Upon analysis, the VN control returned 9 matches for 
theoretical peptides generated after trypsin digestion. Interestingly, no matches were observed 
N-terminal to amino acid 187. Chimera A retrieved 8 positive specific matches to the 
expected sequence. Of these 8, 5 peptides concurred with the VN portion, with the most 
upstream thereof being at amino acid 177, whilst 3 peptides pertained to sequences within the 
IGF-I portion of the chimeric protein. Chimera B on the other hand had 4 positive matches, 
with 2 in each of the VN and IGF-I regions. Here the most N-terminal fragment started at 
amino acid 198. Chimeras C and D both returned 3 positive matches. However, all 3 peptides 
corresponded to the IGF-I portion of the chimeras and there were no matches to any part of 
their VN segments. 
[Insert Table VI about here] 
 
Receptor blocking cell migration. As described above, Chimeras B and D, at 10x and 30x 
respectively, were found to induce cell migration to levels similar to that found with the 1x 
VN:IGFBP-3:IGF-I complex; hence these chimeras were selected for further evaluation in 
migration assays employing function blocking antibodies. Assays of each treatment without 
antibody were defined as 100% and the relative inhibitory effect of the function-specific 
blocking antibodies determined (Fig. 4). The anti IGF-1R antibody reduced cell migration of 
VN alone by 30% while the anti-αv-integrin antibodies significantly decreased migration by 
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70%. Similarly, treatments of the VN:IGFBP-3:IGF-I complex showed reduced migration by 
30% and 56% in the presence of anti-IGF-1R and anti-αv-integrin antibodies, respectively. 
Interestingly, incubation of the cells with function blocking antibodies was more effective in 
assays of chimeras B and D. Thus, when anti-IGF-1R antibodies were included with chimera 
B, cell migration was reduced by 64% while the addition of anti-αv-integrin antibodies 
inhibited migration by 83%. Similar results were observed with chimera D, where cell 
migration was decreased by more than 60% and 80% when the cells were pre-incubated with 
anti-IGF-1R and anti-αv-integrin antibodies, respectively.  
[Insert Figure 4 about here] 
 
Cell signalling activation. To determine if the chimeric proteins could activate intracellular 
signalling in a similar fashion to the VN:IGFBP-3:IGF-I complexes (Hollier et al. 2007), 
phosphorylation of ERK 1/2 and AKT was examined (Fig. 5). Cells were incubated with 
concentrations of the controls (VN, VN:IGFBP-3:IGF-I and VN:IGF-I) and chimeric proteins 
(chimeras B and D) equivalent to those found to be the most effective in stimulating MCF-7 
migration (that is 1x for the controls, 10x for chimera B and 30x for chimera D) for time 
periods of 10 and 60 minutes. At both time points the VN alone control stimulated 
phosphorylation of ERK 1/2 while no activation of AKT was observed. Both VN:IGF-I and 
the VN:IGFBP-3:IGF-I complex, however, were effective in stimulating phosphorylation of 
both ERK 1/2 and AKT. Chimera D was able to stimulate ERK 1/2 and AKT phosphorylation 
to levels comparable to the multiprotein VN:IGFBP-3:IGF-I complex, at both time points 
tested. Chimera B on the other hand did not stimulate activation of ERK 1/2 to the same 
extent as chimera D or the VN:IGFBP-3:IGF-I complex, nor did it stimulate phosphorylation 
of AKT whatsoever. The activation stimulated by chimera B was instead similar to that 
induced by VN alone. 
[Insert Figure 5 about here] 
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Cell proliferation. To ascertain whether the IGF-I domain of chimeras B and D retained 
biological function, we assessed the ability of these chimeras to stimulate cell proliferation in 
the MCF-7 cells. We have previously found that unlike the situation in cell migration assays 
VN alone, or added to IGF-I ± IGFBP treatments, has little effect on MCF-7 proliferative 
responses leading us to deduce that the proliferative responses induced by the trimeric 
VN:IGFBP-3:IGF-I complexes is primarily due to the presence of IGF-I (Hollier et al. 2007). 
Hence, the ability of chimeras B and D to promote cell proliferation was assessed in 96 hr cell 
growth assays (Fig. 6). The treatments assessed were of the same molar ratios as used in the 
cell migration assays. All concentrations of VN alone were ineffective at inducing cell 
growth, while VN:IGF-I and the VN:IGFBP:IGF-I complex were able to significantly 
enhance cell proliferation above the control. Cells treated with 10x Chimera B, 30x Chimera 
D and 1x VN:IGFBP:IGF-I complex showed equivalent stimulation of cell proliferation. 
[Insert Figure 6 about here] 
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Discussion 
 
We have previously reported that insulin-like growth factor-I (IGF-I) binds to the extra-
cellular matrix protein vitronectin (VN) via the involvement of select IGF-binding proteins 
(IGFBPs) (Kricker et al. 2003). Further, we have comprehensively demonstrated that these 
multiprotein complexes significantly enhance cell growth and migration in a range of cells, 
including continuous cell lines (Kricker et al. 2003; Noble et al. 2003; Hyde et al. 2004; 
Hollier et al. 2005), cells derived from primary tissues and used for the production of clinical 
grafts, and more recently, cells involved in the re-epithelialization of wounds in vivo (Upton 
et al. 2007). Furthermore, the activity of the multiprotein complex has been shown to depend 
on the co-activation of IGF-I and VN-binding cell surface receptors (Hollier et al. 2007; 
Upton et al. 2007). Currently, translation of the VN:IGFBP:IGF-I complex technology into 
approved cell culture reagents and clinical treatments is limited to some extent by the fact that 
each of the components needs to be produced recombinantly, along with the cost and complex 
methodology required for the incorporation of three separate components into one effective 
treatment. In order to address these limitations, we hypothesised that the functional 
constituents of the complexes could be reproduced in a single protein that could emulate the 
enhanced cellular responses previously observed with the multiprotein complex (Kricker et al. 
2003; Hyde et al. 2004; Hollier et al. 2005; Schleicher et al. 2005; Ainscough et al. 2006; 
Dawson et al. 2006). The aim of this investigation therefore was to produce unique protein 
species that incorporated the critical functional elements of the VN:IGFBP:IGF-I complex in 
one bio-active protein and in doing so, facilitate the translation of this technology into clinical 
and industrial therapies through improved production efficiencies and reduced development 
costs.  
As described herein, 4 recombinant chimeric proteins incorporating specific domains 
of VN linked to mature IGF-I were designed, expressed and purified (Fig. 1 and 2). 
Critically, functional studies indicate that 2 of these novel recombinant chimeric proteins, 
namely chimeras B and D, can indeed mimic the action of the VN:IGFBP:IGF-I multiprotein 
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complex in cell migration experiments (Fig. 3). However, higher molar ratios of the chimeras 
were required (10x Chimera B and 30x Chimera D) to obtain responses equivalent to the 
VN:IGFBP:IGF-I complex. Despite this need for higher molar amounts of the chimeras, 
chimeric protein treatments able to induce responses equivalent to the VN:IGFBP:IGF-I 
complexes would in fact contain no more than 3 times the total protein, due to the removal of 
the need for the IGFBP and the overall reduced molecular weight of the chimeric proteins. 
We elected to produce these chimeric proteins in an insect cell expression system 
because VN has been successfully produced in insect cells. In addition, we believe post-
translational modifications such as glycosylation may be critical to protein function. 
Therefore, as post-translational modifications and protein processing are suggested to be 
similar in insect cells compared to mammalian systems (Geisse et al. 1996; Hu 2005; 
Harrison and Jarvis 2006), the insect cells were chosen as the most appropriate expression 
system.  In order to verify compliant processing of the N-terminus which contained the native 
human VN secretion signal peptide, chimeras B and D were sequenced. The N-terminal 
sequencing results revealed that the first 8 amino acids of each chimera were identical to 
those of mature human VN from which the signal peptide had been cleaved, confirming 
equivalent processing in this instance (Table V).  
To gain further insights into the structure and processing of the recombinant proteins 
produced, the chimeras were digested with trypsin and interrogated by mass-spectroscopy 
(Table VI). Peptides corresponding to VN were only observed in tryptic-digested 
preparations of human VN and chimeras A and B, and of those fragments, none were more 
N-terminal than amino acid 177 of VN. These findings correlate with those of Josic and 
co-workers who described the presence of VN in ‘pure’ factor IX preparations (Josic et al. 
2001). Analysis of their data reveals that no peptides more N-terminal than amino acid 187 
were detected by MALDI-TOF MS. A possible explanation for these results may be that the 
protein sequence up to amino acid 177, thus the entire VN portion of chimeras C and D, has 
been modified to incorporate factors such as phosphates and carbohydrates. In addition, 
previous studies have demonstrated that stretches of acidic amino acids, such as amino acids 
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52 to 64 of VN, have a low ionization efficiency altering the time of flight of the peptides. 
The presence of such entities has been reported to interfere with the tryptic cleavage reaction 
and/or alters the mass of fragments containing such modifications or characteristics, thus 
making them impossible to match with theoretical tryptic peptide masses (Ewing and Cassady 
2001). Each chimera, however, gave consistent results with 2 to 3 positive fragments 
homologous to the IGF-I portion, indicating homology to this aspect of their original designs.  
The data indicating that chimeras B and D are functionally equivalent to the 
VN:IGFBP:IGF-I complex in cell migration assays, whereas chimeras A and C are not is 
perplexing. Presumably this lack of activity is due to unfavourable folding resulting in a 
conformation that may inhibit activation of one or both of the αv-integrins and IGF-1R. 
However, there are many examples of the compatibility of insect and mammalian systems in 
the literature (Geisse et al. 1996), and given that two of the four chimeras were able to 
promote cellular responses equivalent to the VN:IGFBP:IGF-I complex, it is unlikely that 
post-translational modifications performed by the insect cells caused chimeras A and C to 
function poorly. Another aspect that may impact the biological activity of the final chimeric 
protein, however, is the linker sequence itself. The linker sequence used in the chimeras was a 
derivation of those used in previously reported studies in which fragments of the variable 
region of antibodies were linked together, or to other secondary effector molecules, to provide 
therapeutic and diagnostic reagents for a wide variety of uses (Huston et al. 1988; Kortt et al. 
1997; Turner et al. 1997; Hudson 1998). These previous studies demonstrated that the linker 
was able to act as a connecting region with negligible impact on the function of the linked 
entities, thus making the Gly4Ser linker a prime candidate for our chimeric proteins. In 
addition, a recent study by Lynn and co-workers described a detailed structural model of VN 
(Lynn et al. 2005) and on this representative VN structure, the maximum separation of the C-
terminus from the charged regions of the SMB domain is ~75Å. We therefore sought a linker 
sequence that allowed the C-terminal IGF-I domain to interact with all of the VN domains. 
Hence, the VN:IGF-I chimeras we generated incorporated a linker with 4 repeats of the 
Gly4Ser motif since such a linker will span approximately 70Å (assuming an average amino 
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acid length of 3.25Å) and would be quite flexible. Nevertheless, in terms of chimeras A and 
C, further investigations directed at modifying the linker sequence may well result in an 
optimal linker sequence that enables both αv-integrin and IGF-1R receptor activation in these 
chimeras. 
It has been suggested by many that the enhanced cellular responses to IGFs in the 
presence of VN may be a result of “cross-talk” between the IGF-1R and αv-integrins (Zheng 
and Clemmons 1998; Clemmons et al. 1999; Maile et al. 2001). While direct co-operation 
between the IGF-1R and αv-integrins has yet to be determined, the downstream signalling 
pathways are clearly interconnected (Vuori and Ruoslahti 1994; Eliceiri 2001; Clemmons and 
Maile 2005; Maile et al. 2006). Additional investigations also demonstrate that a number of 
growth factor receptors interact with ECM components to modulate cellular functions, 
suggesting that interactions between growth factor receptors and the ECM is important 
(Majack et al. 1986; Nurcombe et al. 2000; Eliceiri 2001; Rahman et al. 2005). In order to 
understand the mechanism by which the multiprotein complex and the VN:IGF-I chimeras 
were acting to induce cell migration, additional migration experiments were performed that 
utilised function blocking antibodies directed against the IGF-1R and αv-integrins (Fig. 4). In 
treatments of VN alone, the VN:IGFBP:IGF-I complex and chimeras B and D, function-
blocking antibodies to the IGF-1R and the αv-integrins abrogate cell migration responses. 
This confirms that co-activation of the VN-binding αv-integrins and the IGF-1R is required to 
confer a migration response. Furthermore, these results corroborate previous studies by others 
in which inhibition of the IGF-1R and αvβ5 integrin reduced IGF-I-stimulated migration on 
VN in MCF-7 cells (Doerr and Jones 1996).  
One mechanism by which growth factor receptors and integrins can collaborate is via 
synergistic responses in their respective down-stream signalling pathways (Plopper et al. 
1995; Miyamoto et al. 1996; Eliceiri 2001). Binding of ligands to both αv-integrins and the 
IGF-1R induces a number of cascades, including the ERK 1/2/MAPK and AKT/PI-3K 
pathways (Klemke et al. 1994; Fincham et al. 2000; Yamboliev et al. 2001; Yamboliev and 
Gerthoffer 2001; Tai et al. 2003; Huang et al. 2004). In addition, activation of both these 
20 
pathways has been implicated in cell motility (Klemke et al. 1997; Fincham et al. 2000; 
Yamboliev et al. 2001; Tai et al. 2003; Huang et al. 2004). Moreover, blocking VN binding to 
αvβ3 via disintegrin antagonists has been demonstrated to abolish IGF-I-stimulated responses 
such as cell migration, IGF-1R autophosphorylation and PI3-K activation (Zheng and 
Clemmons 1998; Clemmons et al. 1999; Ling et al. 2003; Maile et al. 2006). Therefore, we 
investigated the ability of the VN:IGFBP:IGF-I complex and chimeras B and D to induce 
activation of these pathways. We document here that VN:IGFBP:IGF-I complexes, along 
with chimeric proteins B and D, can stimulate transient and synergistic activation of the ERK 
1/2/MAPK signalling pathway. Coincidently, both the multiprotein complex and chimera D 
produced a sustained activation of the AKT/PI3-K pathway (Fig. 5). When compared to the 
VN:IGFBP:IGF-I treatment, only chimera D was equivalent in the level of phosphorylated 
ERK 1/2 and AKT present, while chimera B was only able to activate the signalling 
molecules to levels found with VN alone. These results demonstrate that chimera D and the 
VN:IGFBP:IGF-I complex are similar functionally. Thus the synergistic increases in cell 
signalling observed in response to the VN:IGFBP:IGF-I complex and chimera D appear to 
arise from co-activation of both the IGF-1R and αv-integrins through the concomitant 
delivery of both IGF-I and VN (or fragments there of) to the cell surface, since substantial 
activation of the AKT/PI3-K pathway required both components to be present (Fig. 5).  
In addition to cell migration, the proliferation of cells is another key response critical 
for successful cell growth and repair processes. Furthermore, a significant number of growth 
factor chimera studies have used cell proliferation experiments to characterise the novel 
proteins (Congote and Li 1994; Congote 1995; Difalco and Congote 1997; Michieli et al. 
2002; Sandoval et al. 2002; Sandoval et al. 2003; Brewster et al. 2004; Brewster et al. 2006; 
Ishikawa et al. 2006). Therefore, the chimeric proteins that mimicked responses to 
VN:IGFBP-3:IGF-I complexes in cell migration assays, namely chimeras B and D, were 
assessed for their ability to induce cell growth using MCF-7 breast carcinoma cells (Fig. 6). 
As per the cell migration assays, both chimeric proteins were able to significantly increase 
cell number equivalent to the VN:IGFBP-3:IGF-I multiprotein complex. These results 
21 
indicate that the IGF-I portion of the chimeras confer function in terms of cell proliferation. 
Moreover, these results further demonstrate that chimeras B and D and the VN:IGFBP:IGF-I 
complexes are equivalent functionally in terms of cell proliferation. 
Recent studies in other laboratories have also drawn attention to the potential of 
combining proteins with functionally disparate properties into one molecule to generate novel 
proteins with activity surpassing that of the individual components alone. For example, basic 
fibroblast growth factor (bFGF) was linked to the ECM heparin-binding growth-associated 
molecule and this novel protein has been demonstrated to enhance re-endothelialisation in 
injured arteries above that obtained with bFGF alone (Brewster et al. 2006). Another recent 
report describes the linkage of the anti-viral protein interferon-α (IFN-α) to human serum 
albumin (Balan et al. 2006). The resultant chimera sustained the activity of the IFN-α portion 
whilst the stabilizing proteolytic antagonist properties of albumin were retained. Furthermore, 
Ishikawa et al. (2006) utilised the collagen binding domain of FN to locate a non-heparin 
binding mutant of vascular endothelial growth factor (VEGF), VEGF121, to the ECM 
(Ishikawa et al. 2006). In this situation the focal concentration of VEGF121 was sustained in 
a collagen matrix to promote enhanced growth and differentiation of endothelial cells 
(Ishikawa et al. 2006).  
These recent reports, taken together with the novel data we present herein, highlight 
the importance of interactions between ECM proteins and growth factors. In addition, these 
data confirm that co-ordinate activation and “cross-talk” between the IGF-I receptor and the 
VN-binding αv-integrins underlie the enhanced responses observed in cells exposed to the 
VN:IGFBP:IGF-I multiprotein complexes (Hollier et al. 2007; Upton et al. 2007). 
Furthermore, we demonstrate that these responses can be recapitulated in a single 
recombinant chimeric protein. Critically, these experimental data have important implications 
in terms of reducing manufacturing costs and addressing regulatory issues in translating these 
ECM protein:growth factor complexes into industrial-scale cell culture applications, as well 
as cell-based regenerative therapies and wound healing applications. 
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TABLE I 
 
Primer sequences for site-directed mutagenesis PCRs.  
 
Construct / 
Modification Sense Primer Anti-sense Primer 
Chimera A / 
linker 
insertion 
5′-p-GGTGGTGGTGGTTCCGGTGGTGGTGGTTCC 
GGTGGTGGTGGTTCCGGTGGTGGTGGTTCCAAC 
GGTCCTGAGACCCTGTGCGGT-3′ 
5′-CAGGTGGCCAG 
GAGCA-3′ 
Chimera B / 
linker 
insertion 
5′-p-GGTGGTGGTGGTTCCGGTGGTGGTGGTTCC 
GGTGGTGGTGGTTCCGGTGGTGGTGGTTCCAAC 
GGTCCTGAGACCCTGTGCGGT-3′ 
5′-ACGAGTACCAG 
CGGAGGTACG-3′ 
Chimera C / 
linker 
insertion 
5′-p-GGTGGTGGTGGTTCCGGTGGTGGTGGTTCC 
GGTGGTGGTGGTTCCGGTGGTGGTGGTTCCAAC 
GGTCCTGAGACCCTGTGCGGT-3′ 
5′-ACCAGGGTGCA 
GAGTCTCAGG-3′ 
Chimera D / 
linker 
insertion 
5′-p-GGTGGTGGTGGTTCCGGTGGTGGTGGTTCC 
GGTGGTGGTGGTTCCGGTGGTGGTGGTTCCAAC 
GGTCCTGAGACCCTGTGCGGT-3′ 
5′-CTCCTCGCCGTCGT 
CGTACAC-3′ 
All chimeras / 
TEV insertion 
5′-p-GACAACCTGTACTTTCAGGGTAAGCCTAT 
CCCTAA-3′ 
5′-AGCGGACTTAG 
CAGGC-3′ 
 
Sense primers bound downstream on the coding sequence whilst anti-sense primers bound 
upstream. Amplification occurred in opposite directions and continued along the complete 
template length of the synthetic genes. 
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TABLE II 
 
Treatment schedule for TranswellTM migration assays 
 
Treatments 
Treatments 
1x 3.3x 10x 30x 
VN 1 µg/mL 3.3 µg/mL 10 µg/mL   
Trimeric 
Complex 
1 µg/mL VN 
1 µg/mL  
IGFBP3 
0.3 µg/mL IGF-I 
3.3  µg/mL VN 
3.3  µg/mL 
IGFBP3 
1 µg/mL IGF-I 
10 µg/mL VN 
10 µg/mL 
IGFBP3 
3 µg/mL IGF-I 
  
  
  
Chimera A 1 µg/mL 3.3 µg/mL 10 µg/mL   
Chimera B 0.67 µg/mL 2.21 µg/mL 6.7 µg/mL   
Chimera C 0.26 µg/mL 0.86 µg/mL 2.6 µg/mL   
Chimera D 0.14 µg/mL 0.46 µg/mL 1.4 µg/mL 4.2 µg/mL 
 
The composition and concentration of the treatments used in the cell migration assays 
assessing the chimeric proteins is indicated. The proteins were added in 1 mL of SFM to the 
lower chamber of the TranswellTM plates prior to seeding cells into the upper chamber inserts.  
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TABLE III 
 
Treatment schedule for cell signalling assays 
 
Treatments Concentration 
VN 2.50 µg/mL 
Trimeric 
Complex 
2.50 µg/mL VN 
2.50 µg/mL IGFBP-3 
0.75 µg/mL IGF-I 
VN + IGF-I 
2.50 µg/mL VN 
0.75 µg/mL IGF-I 
Chimera B 16.75 µg/mL 
Chimera D 10.50 µg/mL 
 
The composition of the treatments used in the cell signalling assays assessing the chimeric 
proteins is indicated. The proteins were added to the wells of a 6-well plate in 1 mL SFM. 
The final concentrations of the proteins assessed, after the addition of cells to the wells, are 
indicated above. 
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TABLE IV 
 
Treatment schedule for proliferation assays 
 
Treatments 
Treatments 
0.33x 1x 3x 10x 30x 90x 
VN 0.28 µg/mL 0.83 µg/mL 2.50 µg/mL       
Trimeric 
Complex 
0.28 µg/mL VN 
0.28 µg/mL 
 IGFBP3 
0.08 µg/mL IGF-I 
0.83 µg/mL VN 
0.83 µg/mL 
IGFBP3 
0.25 µg/mL IGF-I 
2.50 µg/mL VN 
2.50 µg/mL 
IGFBP3 
0.75 µg/mL IGF-I 
  
  
  
  
  
  
  
  
  
VN + IGF-I 
0.28 µg/mL VN 
0.08 µg/mL IGF-I 
0.83 µg/mL VN 
0.25 µg/mL IGF-I 
2.50 µg/mL VN 
0.75 µg/mL IGF-I 
   
Chimera B     1.86 µg/mL (3.3x) 5.58 µg/mL 16.75 µg/mL   
Chimera D       1.16 µg/mL 3.50 µg/mL 10.50 µg/mL 
 
The composition of the treatments used in the proliferation assays assessing the chimeric 
proteins is indicated. The proteins were added to the wells of a 96-well plate in 50 µL SFM. 
The final concentrations of the proteins assessed, after the addition of cells to the wells, are 
indicated above. 
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TABLE V 
 
N-terminal sequencing results for Chimeras B and D. 
 
Position Chimera B Chimera D VN 
1 D D D 
2 Q Q Q 
3 E E E 
4 S S S 
5 - - C 
6 K K K 
7 G ( G ) G 
8 R ( R ) R 
 
The first eight amino acids of the N-terminus of chimeras B and D were determined using the 
Edman degradation method. ‘-’ = C or modified amino acid, ‘( )’ = tentative assignment. The 
mature VN N-terminal sequence is detailed in the far right row (Fryklund and Sievertsson 
1978). The single letter amino acid code is depicted. 
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TABLE VI 
 
Mass-Spectrum results for the chimeric proteins.  
Protein Mass ∆Mass Positive sequence Position VN IGF-I 
VN 875.561 -0.087 (R)/QPQFISR/(D) 331-337    
  887.599 -0.087 (K)/AVRPGYPK/(L) 187-194    
  988.623 -0.097 (R)/ERVYFFK/(G) 269-275    
  1314.82 -0.142 (R)/RVDTVDPPYPR/(S) 453-463    
  1422.817 -0.163 (R)/FEDGVLDPDYPR/(N) 230-241    
  1448.928 -0.195 (K)/TYLFKGSQYWR/(F) 219-229    
  1448.928 -0.167 (R)/TSAGTRQPQFISR/(D) 325-337    
  1647.001 -0.183 (R)/DVWGIEGPIDAAFTR/(I) 198-212    
  1666.962 -0.186 (R)/DWHGVPGQVDAAMAGR/(I) 338-353    
A 1304.585 -0.038 (R)/GQYCYELDEK/(A) 177-186    
  1314.730 -0.049 (R)/RVDTVDPPYPR/(S) 453-463    
  1422.709 -0.055 (R)/FEDGVLDPDYPR/(N) 230-241    
  1646.870 -0.052 (R)/DVWGIEGPIDAAFTR/(I) 198-212    
  1666.793 -0.017 (R)/DWHGVPGQVDAAMAGR/(I) 338-353    
  1667.827 -0.045 (R)/GFYFNKPTGYGSSSR/(R) 521-535    
  1708.842 -0.052 (R)/RAPQTGIVDECCFR/(S) 536-549    
  2530.387 -0.057 
(K)/SAENLYFQGKPIPNPLLGLD 
STR/(T) 568-590    
B 1422.750 -0.096 (R)/FEDGVLDPDYPR/(N) 230-241    
  1646.913 -0.095 (R)/DVWGIEGPIDAAFTR/(I) 198-212    
  1667.885 -0.103 (R)/GFYFNKPTGYGSSSR/(R) 373-387    
  2530.439 -0.109 
(K)/SAENLYFQGKPIPNPLLGLD 
STR/(T) 420-442    
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C 1667.992 -0.210 (R)/GFYFNKPTGYGSSSR/(R) 188-202    
  2530.546 -0.216 
(K)/SAENLYFQGKPIPNPLLGLD 
STR/(T) 235-257    
D 1668.017 -0.235 (R)/GFYFNKPTGYGSSSR/(R) 126-140    
  1709.021 -0.231 (R)/RAPQTGIVDECCFR/(S) 141-154    
  2530.633 -0.303 
(K)/SAENLYFQGKPIPNPLLGLD 
STR/(T) 173-195    
 
Expected amino acid sequences and peptide masses of tryptic-digested samples of the 
chimeric proteins were entered into the FindPep program on the Expasy website 
(www.expasy.org). Positive matches were determined to pertain to regions of the VN or 
IGF-I portions of the chimeras. The “Mass” column indicates experimentally-derived masses, 
“∆Mass” indicates difference between experimentally-derived and theoretical masses. ’/’ 
indicate cleavage sites and bracketed ‘( )’ letters denote amino acids preceding and following 
the peptides N- and C-terminal cleavage sites. 
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FIGURE LEGENDS 
 
Figure 1: Schematic representation of the chimeric proteins and amino acid sequences 
encoded by the chimeric expression constructs. i. All chimeric proteins contain the 
(Gly4Ser)4Asn linker motif (LINK) and the mature IGF-I molecule (IGF-I). Chimera A (A) 
contains the full-length VN molecule (amino acids 1 – 459) including the somatomedin-B 
domain (SMB), the integrin binding RGD domain (RGD), the connecting region (CON), the 
heamopexin-like 1 domain (HEM 1) and the heamopexin-like 2 domain (HEM 2). Chimera B 
(B), comprises amino acids 1 – 311 of VN and excludes the heparin binding domain. Chimera 
C (C), comprises amino acids 1-125 of VN, while Chimera D (D), comprises amino acids 1-
64 of VN, and is truncated at the end of the polyanionic region (- - - ). ii. All constructs 
contain DNA sequences encoding the secretion signal peptide of human VN (1-19) followed 
by DNA encoding: select amino acid sequences of the mature VN protein (purple 
highlighted); a (Gly4Ser)4Asn linker sequence (green highlighted); the mature IGF-I sequence 
(blue highlighted); and the TEV cleavage site, V5 epitope and the 6x His tag (underlined) are 
at the C-terminal end of the protein. 
 
Figure 2: Purified chimeric VN:IGF-I proteins. Chimeric proteins A, B, C and D were 
purified using a variety of chromatographic methods as described in the Materials and 
Methods. Purity of the chimeras was assessed using Silver-Stained SDS-PAGE gels (left-hand 
lane in each pair) and Western blotting utilizing a polyclonal anti-VN antibody (right-hand 
lane in each pair). Molecular weight markers are indicated. 
 
Figure 3: Chimeric VN:IGF-I proteins stimulate cell migration in MCF-7 cells. 
TranswellTM migration assays were performed with treatments of SFM (negative control), VN 
alone, the trimeric VN:IGFBP-3:IGF-I complex, as well as chimeric proteins A, B, C and D at 
the concentrations indicated in Table 2. Data is expressed as % of VN alone at 1x dose. 
Values shown are mean ± SEM of independent triplicate treatments present in 2 replicate 
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experiments. Asterisks (*) indicate treatments where migration was significantly different 
(p<0.01) compared to the 1x VN alone, while crosses (†) indicate treatments where migration 
was not significantly different (p>0.05) compared to the trimeric 1x VN:IGFBP-3:IGF-I 
complex. 
 
Figure 4: Function blocking antibodies inhibit chimera induced cell migration. Chimeras B 
and D showed similar activity to the VN:IGFBP-3:IGF-I complex in TranswellTM migration 
assays, thus these chimeras were further characterised in migration assays utilising function-
blocking antibodies. Treatments of VN alone, the VN:IGFBP-3:IGF-I complex at 1x 
concentration, and chimeric proteins B, at 10x, and D, at 30x, were assessed in Transwell™ 
migration assays; cells for each treatment were pre-incubated with no antibody (white bars), 
IgG control (25 µg/mL, shaded bars), anti-IGF-IR (10 µg/mL, dark blue bars) and anti-αv-
integrin (1:10, light blue bars) antibodies. Data is expressed for each treatment group as % of 
the migration observed for the treatment with no added antibody. Values shown are mean + 
SEM of triplicate wells from from 2 replicate experiments with independent triplicate 
treatments in each experiment. Asterisks (*) indicate treatments where migration was 
significantly different (p<0.01) compared to the control treatment within each group (no 
added antibody).  
 
Figure 5: Phosphorylation of ERK 1/2 and AKT in MCF-7 cells. Total protein was extracted 
from MCF-7 cells treated with VN alone, the trimeric VN:IGFBP-3:IGF-I complex, VN and 
IGF-I, chimera B and chimera D, at the concentrations indicated in Table 3.3, at 10 minutes 
(10’) and 60 minutes (60’). Cell lysates were probed for phosphorylated (pERK 1/2 and 
pAKT) and total (ERK 1/2 and AKT) forms of ERK 1/2 and AKT in western blots. 
 
Figure 6: Chimeric VN:IGF-I proteins stimulate MCF-7 cell proliferation. Treatments of 
SFM (negative control), VN alone, VN + IGF-I, the VN:IGFBP-3:IGF-I complex, as well as 
chimeras B and D, were assessed in cell proliferation assays. Data is expressed as % above 
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the SFM control. Values shown are mean + SEM from 2 replicate experiments with 
independent triplicate treatments in each experiment. Asterisks (*) indicate treatments where 
migration was significantly different (p<0.05) compared to the control (SFM). Crosses (†) 
indicate treatments where proliferation was not significantly different (p>0.05) compared to 
the 1x VN:IGFBP-3:IGF-I complex. 
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